Xcelom Limited was founded by the inventors of non-invasive prenatal test in 2014. We hold the exclusive license of NIPT and are the first provider of Non-invasive Prenatal Testing (NIPT) services in Hong Kong.
The test utilizes the latest genomic technology which provides a highly sensitive, reliable and accurate prenatal screening method for the public.
Early screening is beneficial to premutation carriers and their families for better arrangement on medical and genetic counselling.
View our upcoming and past events
After years of dedicated research, methods for the non-invasive screening of fetal chromosomal aneuploidies, were successfully achieved. Learn more about Xcelom with in-depth and original news, interviews and articles.
adopts the latest and patented Non-invasive
Prenatal Testing Technology (NIPT) for the screening of fetal chromosomal
aneuploidies including Down Syndrome (T21), Edwards Syndrome (T18), Patau
Syndrome (T13), Sex Chromosome Aneuploidies and microdeletion/microduplication
all in ONE test. Compared to traditional methods, is more sensitive, reliable, accurate,
informative and most importantly, remove the risk of miscarriage.
Parents who have the conditions below should take advise from their healthcare provider:
- Present or known history of tumor, uterine fibroids;
